CTX120 / CRISPR Therap - LARVOL DELTA

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=26 | Terminated | Sponsor: CRISPR Therapeutics AG | Active, not recruiting ➔ Terminated; Patients to be followed up in the CRSP-ONC-LTF study

Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

[VIRTUAL] BCMA-Directed CAR T-Cells: Early Results and Future Directions (SOHO 2021) - "Other Constructs of Interest Orva-cel (orvacabtagene autoleucel) is an anti-BCMA CAR T product with a construct containing a fully human scFv, an optimized spacer, a 4-1BB co-stimulatory domain, and a CD3z activation domain...Bb21217 has an identical construct to ide-cel except for coculturing with the phosphoinositide 3 kinase inhibitor (PI3K) bb007 during ex vivo culture to enrich for T cells displaying a memory-like phenotype...The ORR was 94%.17 P-BCMA-101 is a novel construct using an anti-BCMA Centyrin™ fused to a 4-1BB costimulatory domain and CD3z signaling domain...Both ide-cel and cilta-cel are being evaluated in various patient populations, including early-relapse and newly diagnosed high-risk patients...The first results of an allogeneic BCMA-directed CAR-T was with ALLO-715. The initial results from the UNIVERSAL phase 1 study in RRMM are encouraging, with responses reported and more attenuated toxicity.26 Others, including CTX120, BCMAUCART, UCART CS1, and..."

CAR T-Cell Therapy • Hematological Malignancies • Multiple Myeloma • Oncology • CD19 • CD4 • CD8 • SDC1 • TNFA

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) - "CRISPR Therapeutics continues to enroll and dose patients in the pivotal trial of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19+ B-cell malignancies. The Company expects to report additional data in 2022....CRISPR Therapeutics’ Phase 1 clinical trials for CTX-120...and CTX130...are ongoing....The Company expects to provide updates from each trial in the first half of 2022."

Clinical • P1 data • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: CRISPR Therapeutics AG | Recruiting ➔ Active, not recruiting | N=80 ➔ 26

Enrollment change • Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire) - "The pharmacokinetic data provide a strong rationale that consolidation dosing can improve on an already competitive profile for CTX110. Based on the safety and efficacy profile, the Company plans to expand into a potential registrational trial that incorporates consolidation dosing in Q1 2022....Company is implementing consolidation dosing protocols for its CTX120 and CTX130 clinical trials and expects to report top-line data in the first half of 2022."

New trial • Hematological Malignancies • Multiple Myeloma • Oncology

CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire) - “CRISPR Therapeutics…announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, to be held both virtually and at the Walter E. Washington Convention Center in Washington, D.C., from November 10 to 14, 2021. The Company also announced an oral presentation at the SITC 2021 Pre-Conference Program, The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations, which will be held from 2:00 p.m. – 6:00 p.m. ET on November 10, 2021.”

Preclinical • Oncology • Solid Tumor

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results (GlobeNewswire) - "The Company expects to report additional clinical data in 2021 from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of several dose levels of CTX110...for the treatment of relapsed or refractory B-cell malignancies...The Company expects to report top-line data from...Phase 1 clinical trial assessing the safety and efficacy of several dose levels of CTX120 for the treatment of relapsed or refractory multiple myeloma...in 2021."

P1 data • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results (GlobeNewswire) - "The Company expects to report additional data in 2021 from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of several dose levels of CTX110...for the treatment of relapsed or refractory B-cell malignancies...The Company expects to report top-line data from...Phase 1 clinical trial assessing the safety and efficacy of several dose levels of CTX120...for the treatment of relapsed or refractory multiple myeloma...trial in 2021."

P1 data • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results (GlobeNewswire) - "CRISPR Therapeutics announced positive top-line results from its ongoing Phase 1 CARBON trial...for the treatment of relapsed or refractory B-cell malignancies. The Company expects to report additional data from this trial in 2021. CRISPR Therapeutics’ Phase 1 clinical trial assessing the safety and efficacy of several dose levels of CTX120...for the treatment of relapsed or refractory multiple myeloma, is ongoing. The Company expects to report top-line data from this trial in 2021. CRISPR Therapeutics’ two independent Phase 1 clinical trials assessing the safety and efficacy of several dose levels of CTX130...for the treatment of both solid tumors and certain hematologic malignancies, are ongoing. The Company expects to report top-line data from these trials in 2021."

P1 data • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results (GlobeNewswire) - “On October 21, 2020, CRISPR Therapeutics announced positive top-line results from its ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110…The Company expects to report additional data from this trial in 2021…[for CTX120] The Company expects to report top-line data from this trial in 2021…[for CTX130] The Company expects to report top-line data from this trial in 2021.”

P1 data • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Needham sees upside for CRISPR Therapeutics with Q4 catalysts approaching (SeekingAlpha) - "Crispr is expected to announce initial data from the Phase 1/2 trial of CTX110 in r/r Non-Hodgkin Lymphoma and additional data from Phase 1/2 trials of CTX001 in Sickle Cell Disease and Beta Thalassemia in 4Q20. Initial data from Phase 1/2 trials of CTX120 and CTX130 are expected next year."

P1/2 data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CRISPR Therapeutics: A review of its clinical pipeline and progress (SeekingAlpha) - "CRISPR believes that CRISPR-edited allogeneic CAR-Ts has the potential to improve cell persistence as well as overall safety and potency. Its first 2 programs target well-validated targets with the potential to be best-in-class. CTX100 is an anti-CD19 CAR T targeting B-cell malignancies while CTX120 is an anti-B-Cell Maturation Antigen ('BCMA') targeting multiple myeloma. Both trials are currently enrolling patient..."

Enrollment open

CRISPR Therapeutics provides business update and reports fourth quarter and full year 2019 financial results (GlobeNewswire, CRISPR Therapeutics AG) - "...'we have begun enrolling patients in a clinical trial for our second allogeneic CAR-T therapy, CTX120, targeting BCMA for the treatment of relapsed or refractory multiple myeloma'."

Enrollment status

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: CRISPR Therapeutics AG

New P1 trial